Allergan reports new Viberzi data — Drug effective in patients with prior loperamide use

Allergan released data from two phase III studies evaluating the efficacy and safety of Viberzi.

Here's what you should know:

1. Researchers conducted two studies evaluating approximately 2,500 irritable bowel syndrome with diarrhea patients. Around 36 percent of those patients used loperamide in the 12 months prior.

2. Viberzi safely and effectively treated IBS-D symptoms, including abdominal pain and diarrhea, in patients who used loperamide.

3. The analysis also demonstrated the safety and efficacy of Viberzi in patients who used loperamide rescue medication.

4. Allergan Chief Research and Development Officer David Nicholson, PhD, said in a release, "These results continue to build on the robust clinical profile that has already been established, and further underscores Viberzi as a safe and effective treatment option for patients suffering from inadequate symptom control associated with a commonly used treatment for IBS-D."

More articles on gastroenterology:
New York hospital planning surgery center — 4 key notes
GI leader to know: Dr. D. Isaac Gaines of Gastroenterology Associates
GI center to know: Utah Gastroenterology

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers